In a phase IIb clinical trial, 288 patients were randomly assigned to receive 1200 or 800 mg of lanifibranor or placebo once daily for 24 weeks
A clinician may consider combination therapy when metformin alone does not meet individualized glucose goals, when weight is a major treatment factor, or when a GLP-1 receptor agonist fits the broader cardiometabolic plan
J Exp Med (2018) 215(1):11540
A different analysis that included people stopping various weight-loss medications (including liraglutide, semaglutide, tirzepatide) found that, regardless of the medication, people tend to start regaining weight around 8 weeks after stopping
In a lawsuit filed in federal court in New Jersey, Novo argued that Lilly has been comparing the highest doses of its weight loss drug Zepbound and diabetes drug Mounjaro with lower doses of Novos Wegovy and Ozempic